[VIRTUAL] Milademetan, an oral MDM2 inhibitor, in well-differentiated/dedifferentiated liposarcoma: results from a phase 1 study in patients with solid tumors or lymphomas

[VIRTUAL] KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation

[VIRTUAL] KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation

[VIRTUAL] Phase 1 safety, pharmacokinetic and pharmacodynamic study of fadraciclib (CYC065), a cyclin dependent kinase inhibitor, in patients with advanced cancers (NCT02552953)

[VIRTUAL] Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling

[VIRTUAL] Preliminary results from an open-label, multicenter phase 1/2 dose escalation and expansion study of THOR-707, a novel not-Alpha IL-2, as a single agent in adult subjects with sdvanced or metastatic solid tumors

[VIRTUAL] Phase 1/2 study of the safety and efficacy of APL-101, a specific c-MET inhibitor

[VIRTUAL] A phase II study of Guadecitabine (G) with Irinotecan (IRI) vs regorafenib or TAS-102 in metastatic colorectal cancer (mCRC) patients (pts).

[VIRTUAL] Initial results from a Phase 1 Trial of OKI-179, an oral Class 1-selective Depsipeptide HDAC inhibitor, in patients with advanced solid tumors

[VIRTUAL] Continuous vs intermittent adenosine 2A receptor (A2AR) inhibition in preclinical colon cancer (CC) models and in a Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients (pts) with non-small cell lung cancer (NSCLC)

[VIRTUAL] Tumor drug exposure is positively correlated with an improved outcome, in patients with advanced solid tumors, upon treatment with a high dose intermittent sunitinib regimen.

[VIRTUAL] Circulating tumour DNA analysis using three next generation sequencing approaches in a phase 1b trial of ER positive metastatic breast cancer

[VIRTUAL] Phase IIa/IIb clinical trial of NC-6004 (Nanoparticle Cisplatin) plus Pembrolizumab in patients with Head and Neck Cancer (HNSCC) who have failed platinum or a platinum-containing regimen

[VIRTUAL] Clinical pharmacokinetics of adavosertib in the presence or absence of PD-L1 inhibitor durvalumab in patients with refractory solid tumors

[VIRTUAL] Early evidence of dose-dependent pharmacodynamic activity following treatment with SY-5609, a highly selective and potent oral CDK7 inhibitor, in patients with advanced solid tumors